10-Q: BioRegenx Reports Q3 2024 Results, Cites Ongoing Challenges and Restatements

BioRegenx's Q3 2024 report reveals a net loss of $4.65 million, a 39% increase compared to the same period last year, alongside restated financials and identified material weaknesses in internal controls.

Summary

• BioRegenx, Inc. reported its financial results for the third quarter of 2024, showing a net loss of $4.65 million for the nine months ended September 30, 2024, compared to a net loss of $3.34 million for the same period in 2023.
• The company's net sales decreased by 31% to $1.88 million for the nine months ended September 30, 2024, down from $2.73 million in the prior year, primarily due to product issues with their medical testing machine.
• Operating expenses increased to $5.78 million for the nine months ended September 30, 2024, compared to $5.13 million in the same period of 2023, driven by amortization expenses and selling, general and administrative costs.
• The company's cash and cash equivalents decreased to $70,081 as of September 30, 2024, from $125,402 at the end of 2023.
• BioRegenx has restated its financial statements for the three and nine months ended September 30, 2023, due to errors in valuation of assets and capitalization of patent costs.
• The company identified material weaknesses in its internal control over financial reporting, including an ineffective control environment, insufficient segregation of duties, and ineffective controls over the financial statement close and reporting process.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to significant losses, declining sales, restated financials, material weaknesses in internal controls, and a going concern warning. The company's financial health is precarious, and its future is highly uncertain.

Positives

• Cost of sales decreased by 32% for the nine months ended September 30, 2024, compared to the same period in 2023.
• Distributor incentives decreased by 55% for the nine months ended September 30, 2024, compared to the same period in 2023.
• Selling, general and administrative expenses, excluding amortization, decreased by 18% for the nine months ended September 30, 2024, compared to the same period in 2023.

Negatives

• The company experienced a significant decrease in net sales, down 31% for the nine months ended September 30, 2024.
• Returns increased by 388% for the nine months ended September 30, 2024, compared to the same period in 2023.
• The company's net loss increased by 39% for the nine months ended September 30, 2024.
• The company's cash position has significantly weakened, with cash and cash equivalents at $70,081 as of September 30, 2024.
• The company has identified material weaknesses in its internal control over financial reporting.
• Several loans are in default, including $522,500 of notes payable.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and cash flow deficits.
• The company's financial statements have been restated due to errors in valuation of assets and capitalization of patent costs.
• The company has identified material weaknesses in its internal control over financial reporting, which could lead to future misstatements.
• The company is involved in disputes with certain parties, including former officers and board members.
• The company's ability to obtain necessary debt or equity financing is uncertain.
• The company's medical testing machine has experienced product issues, impacting sales and distributor relationships.

Future Outlook

The company anticipates generating losses and may be unable to continue operations in the future. Management intends to raise additional debt or equity financing to fund ongoing operations and for necessary working capital, but there is no assurance that such financing plans will be successful.

Management Comments

• Management has concluded that there is substantial doubt about the Company's ability to continue as a going concern.
• Management intends to raise additional debt or equity financing to fund ongoing operations and for necessary working capital.
• Management has yet to find a solution to its funding requirements.

Industry Context

The company operates in the medical test equipment and nutritional products industry, which is competitive and subject to regulatory changes. The product issues with the medical testing machine highlight the risks associated with product development and quality control in this sector. The company's financial struggles are not uncommon for smaller companies in this industry, which often require significant capital to develop and market their products.

Comparison to Industry Standards

• The company's significant net losses and declining sales are concerning when compared to industry benchmarks for similar companies.
• The company's cash position is significantly weaker than many of its peers, raising concerns about its ability to fund operations and growth.
• The identification of material weaknesses in internal controls is a serious issue that needs to be addressed to ensure the reliability of financial reporting.
• The restatement of financials is a negative signal that can erode investor confidence.
• The company's reliance on debt financing and related party loans is higher than many of its peers, increasing its financial risk.

Legal Proceedings

• The company is involved in disputes with certain parties, including parties that are former officers and board members and vendors associated with their activities.

Related Party Transactions

• The company rents its home office from BBD Holdings, LLC, which is controlled by a significant shareholder and spouse of a director.
• The company has a royalty agreement with the VHS Pool, in which a related entity has a creditor interest.
• The company has a worldwide distribution agreement with GlycoCheck B.V., where former directors may have an ownership interest.
• The company's legal counselors included a member of the board of directors.
• The company reimburses certain officers for company expenses paid through individual accounts.
• The company has financed past activities, in part, with unsecured borrowings from certain related parties.

Stakeholder Impact

• Shareholders are at risk due to the company's financial instability and going concern warning.
• Employees may be impacted by potential layoffs or restructuring due to the company's financial difficulties.
• Customers may be affected by product issues and potential disruptions in service.
• Suppliers and creditors face increased risk of non-payment due to the company's financial struggles.

Next Steps

• The company needs to address the material weaknesses in its internal control over financial reporting.
• The company needs to secure additional debt or equity financing to fund ongoing operations.
• The company needs to resolve the product issues with its medical testing machine.
• The company needs to resolve disputes with certain parties, including former officers and board members.

Key Dates

Keywords

BioRegenx, financial results, net loss, revenue, medical testing, nutritional products, internal control, restatement, going concern, debt, material weakness